Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jiraphun Jittikoon"'
Autor:
Ammarin Thakkinstian, Usa Chaikledkaew, Sermsiri Sangroongruangsri, Jiraphun Jittikoon, Thitiya Lukkunaprasit, Saowalak Turongkaravee
Publikováno v:
The Pharmacogenomics Journal
This meta-analysis was conducted to determine the genotypic effects of rs4149056 and rs2306283 polymorphism in SLCO1B1 gene on myopathy in patients with statin. Studies were searched using multiple databases and selected following inclusion criteria.
Autor:
Usa Chaikledkaew, Surakameth Mahasirimongkol, Jiraphun Jittikoon, Sukanya Wattanapokayakit, Noppadol Chanhom, Wanvisa Udomsinprasert
Publikováno v:
Biomedical Reports
Antituberculosis (anti-TB) drugs are the most common cause of drug-induced liver injury (DILI). There are numerous studies revealing the associations between the polymorphisms of pharmacogenes and the risk of anti-TB DILI (ATDILI). In the present stu
Autor:
Nusara Satproedprai, Noppadol Chanhom, Usa Chaikledkaew, Jiraphun Jittikoon, Surakameth Mahasirimongkol, Sukanya Wattanapokayakit, Taisei Mushiroda, Wanvisa Udomsinprasert, Supharat Suvichapanich
Publikováno v:
Heliyon
Heliyon, Vol 7, Iss 4, Pp e06852-(2021)
Heliyon, Vol 7, Iss 4, Pp e06852-(2021)
Antituberculosis drug-induced liver injury (ATDILI) is the common adverse reaction of antituberculosis drugs. Glutathione S-transferases (GSTs), which are phase II metabolizing enzymes for detoxification, are recognized as potential mediators of hepa
Autor:
Hideki Yanai, Supharat Suvichapanich, Licht Toyo-Oka, Rika Yuliwulandari, Jiraphun Jittikoon, Taisei Mushiroda, Hilyatuz Zahroh, Usa Chaikledkaew, Katsushi Tokunaga, Koya Fukunaga, Sukanya Wattanapokayakit, Surakameth Mahasirimongkol
Publikováno v:
Pharmacogenetics and Genomics. 28:167-176
Background NAT2 slow acetylator is a confirmed risk of anti-tuberculosis drug-induced liver injury (ATDILI). However, NAT2 ultra-slow acetylators, a new refinement among NAT2 slow acetylators, have been recently proposed. The patients with NAT2 genot